Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20‐17/KM23 trial - Kyoungmin Lee; Kyung‐Hun Lee; Dong‐Wan Kim; Jeesun Yoon; Yoon Ji Choi; Soohyeon Lee; Ju Won Kim; Kyong Hwa Park; Wonyoung Choi; Youngjoo Lee; Hyewon Ryu; Dong‐Hoe Koo; et al. (Cancer Communications)